Replies to post #148940 on Cytodyn Inc (CYDY)

[misiu143]

C-20 , well , we could be , and imo , would be if we Gilead , but otherwise ,
It was only phase 2 , only 84 patients in the study ,
we had before only 65 patients in eIND , this in medicine is really a very small number..

So I kind of understand the point ..and they didn't stop us , we may do phase 3 with around 100 patients , we dont need 1000s as others need to prove a point ,
and NEWS2 will be our primary , and they know we will succeed.

And I do believe all this will help us to get EUA in our CD12 , and full approval about 5-6 months later.( Remdesivir got full approval about 5 months after EUA )

Just IMO.

[HighGrowth70]

It was a PII and the Trial size was simply too small. If the Trial (N) had been larger, it likely would have garnered more attention.

And... CYDY is not Big Pharma, with all their $$$, insider connections, and FDA track record...

That will change over time; once CYDY get's their first, second, et-all FDA approvals!

PS: Keep in mind; the small M/M Trial results have informed the Long Hauler Trial design - it has gotten attention. CYDY was correct to abandon the M/M work, focus cash on S/C completion, and prep for Long Haul trial. If/when they receive a S/C approval; that will naturally lead to M/M use via label expansion over time...

The long-game $$$ is in S/C and Long Haul treatments. Given that COVID is now an Endemic virus, there will be an insatiable demand (worldwide) for an effective treatment for both sides of the acute-virus and post-virus phase(s) - over the next many decade(s)...